Xcelerate has unveiled the bioX Genetics Platform, which cuts the time needed to detect genetic variants by 98% and achieves ...

The new data from the PERSEUS and CEPHEUS studies show that Darzalex Faspro®-based regimens achieve up to 95% 4-year PFS and ...

The Phase 3 AMPLITUDE trial showed that adding niraparib to abiraterone acetate and prednisone reduced radiographic ...

Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high ...

The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

The FDA approved darolutamide (Nubeqa®) for metastatic castration-sensitive prostate cancer, based on the Phase III ARANOTE ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease ...

The phase 3 SERENA-6 trial shows that ctDNA-guided early treatment switch to camizestrant plus a CDK4/6 inhibitor in HR+, ...

The first-in-human results for pasritamig, a bispecific T-cell engager, show promising Phase 1 data in heavily pretreated ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...

The Phase III trial showed that the new targeted therapy, inavolisib (Itovebi), provides significant survival benefits for ...